Stroh, Mark

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 163

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 72

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 28

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Stroh, M., Carlile, D., Li, C.-C., Wagg, J., Ribba, B., Ramanujan, S., Jin, J., Xu, J., Charoin, J.-E., Xhu, Z.-X., et al. (2015) · CPT: Pharmacometrics & Systems Pharmacology

Cancer Immunotherapy and BiomarkersStatistical Methods in Clinical Trials

Cited by 16